• About Us

    • Overview
    • Leadership
    • Our Board
    • Scientific Advisors
    • Collaborations

  • Our Technology

    • Overview
    • T-SIGn Platform
    • Unlocking Cell Therapy

  • Our Pipeline

    • Overview
    • Clinical Trials

  • Our News

    • Top News
    • News Archives
    • Media Enquiries
    • Publications

  • More

    Use tab to navigate through the menu items.
    Investors
    Join Us
    Contact Us
    PsiOxus-Therapeutics News-Web-12_edited.jpg

    News Archives

    Top News
    News Archives
    Media Enquiries
    Publications
    2021
    2020
    2019
    2018-2016
    2015 +

    March 13, 2019

    PsiOxus Therapeutics Announces First-in-Human Dosing of their Second Gene Therapy Cancer Treatment.

    Press Release
    Psioxus Corporate Offices
    PsiOxus House
    4-10, The Quadrant,
    Abingdon Science Park
    Barton Lane, Abingdon
    Oxfordshire, OX14 3YS
    United Kingdom
    enquiries@psioxus.com
    +44 (0)1235 835328
    About Us
    Overview
    Leadership
    Our Board
    Scientific Advisors
    Collaborations
    Our Technology
    Overview
    T-SIGn Platform
    Unlocking Cell Therapy
    Our Pipeline
    Overview
    Clinical Trials
    Our News
    Top News
    News Archives
    Media Enquiries
    Publications
    Investors
    Overview
    Contact
    General Enquiries
    Join Us
    Overview
    Submit Resume/CV

    © 2022 PsiOxus Therapeutics All Rights Reserved.

    Terms of Use   |   Privacy Policy   |   Social Media 

    • Psioxus LinkedIn
    • Psioxus Twitter